Highlights Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
2.96 ^USD	+2.07%		+4.23%	+64.44%

Jun. 03	Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	CI
May. 13	Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Jun. 03	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	May. 07	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	Mar. 25	MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	Mar. 25	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human	Mar. 21	MT
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Nov. 02	CI
Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023	23-09-12	CI
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants	23-09-06	CI
Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation	23-09-05	CI
Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation	23-08-16	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Eledon Pharmaceuticals, Inc. Reports Data from Ongoing Phase 1B Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation At World Congress of Nephrology	23-03-31	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Egenesis and Eledon Pharmaceuticals Announces Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies	23-01-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Highlights

Filters